TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05571046
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
Study: NCT05051579
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05051579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05042700
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enema with 25 mg melatonin
Study: NCT05042700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema without melatonin
Study: NCT05062005
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
Study: NCT05982990
Drug: ADVAIR DISKUS® 250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT05692024
Drug: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
Study: NCT05692024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
Study: NCT06071949
Drug: Adezunap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06071949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT04790734
Drug: Sedation drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different sedation drugs
Study: NCT06115993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT05362110
Drug: HCP1803-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05362110
Drug: RLD2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05362110
Drug: HPP2003-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT05362110
Drug: HPP2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT05299398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily
Study: NCT05404243
Drug: phenolization
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of phenolization group, an Abbocath catheter 18 G is introduced into the cystic cavity. Undiluted 88% phenol is instilled into the cavity, ensuring that the cystic cavity is filled. It is maintained for 5 min until complete coagulation of the cyst is achieved.
Study: NCT05924958
Drug: Eprolidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
Study: NCT04811703
Drug: Combined PIPAC / IV chemotherapy treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of cisplatin-doxorubicin PIPAC sessions to carboplatin-paclitaxel systemic Chemotherapy
Study: NCT06533878
Drug: HY-209
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
Study: NCT06085534
Drug: LNK01001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral use
Study: NCT06085534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral use
Study: NCT05505448
Drug: REGN14284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
Study: NCT05505448
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending IV or SC administration per the protocol
Study: NCT04763044
Drug: 250 ppm F as MFP
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT04763044
Drug: 1100 ppm as MFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT04763044
Drug: 2800 ppm F as MFP
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT04763044
Drug: 1100 ppm SnF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be assigned to this treatment during the fifth period for this crossover study.
Study: NCT04968158
Drug: Acetaminophen 325 mg / Tramadol 37.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet, every 8 hours of 325 mg/ 37.5 m
Study: NCT05975749
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Study: NCT04703088
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
Study: NCT06444035
Drug: HA35 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
Study: NCT06012682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin
Study: NCT06427252
Drug: HIPEC
Normalized name: Hyperthermic Intraperitoneal Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
Study: NCT06427252
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;
Study: NCT01132794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nasal saline
Study: NCT00798616
Drug: prednisolone or methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
Study: NCT00798616
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral or IV placebo
Study: NCT04874935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Placebo capsule twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
Study: NCT05529134
Drug: PTW-002 10 mg/g gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: poloxamer hydrogel for topical administration
Study: NCT05054140
Drug: Placebo matching IMU-838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IMU-838 tablets
Study: NCT04172376
Drug: Conservative medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
Study: NCT05316220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05813860
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
Study: NCT04921566
Drug: Toradiur® tablet 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
Study: NCT05190419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT05310760
Drug: Vit C
Normalized name: M-Vit Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
Study: NCT05711719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered the same way
Study: NCT02528708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution
Study: NCT05117736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
Study: NCT06164743
Drug: VVN461 Ophthalmic Solution 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular drug
Study: NCT06164743
Drug: VVN461 Ophthalmic Solution 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular drug
Study: NCT06164743
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular drug
Study: NCT04920617
Drug: CPA
Normalized name: MCPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg twice daily, week on then week off
Study: NCT06371196
Drug: Babaodan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
Study: NCT06241235
Drug: ZG005 Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Study: NCT04443868
Drug: Nitric Oxide-Releasing Drug
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal Spray + Nasal Irrigation
Study: NCT05648266
Drug: Continous SAPB (Ropivacain)
Approvals — FDA: no, EMA: no, PMDA: no
Description: postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
Study: NCT05937490
Drug: long GnRH agonist or flexible GnRH antagonist protocol.
Approvals — FDA: no, EMA: no, PMDA: no
Description: During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
Study: NCT06256588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an IV infusion
Study: NCT04508166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers receive an oral (saline) or sublingual (orodispersible tablet) at scheduled bedrest in the sleep laboratory
Study: NCT05919017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05022186
Drug: Homotaurine
Normalized name: N-Acetylhomotaurine
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will use it with specific instructions and they will be monitored at least one time in a month
Study: NCT06379165
Drug: Meloxicam Nanocrystal Injection
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg (1 mL), once daily, by intravenous infusion
Study: NCT06379165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL Placebo, once daily, by intravenous infusion
Study: NCT06055179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, for 3 cycles of chemotherapy.
Study: NCT05176964
Drug: CAPOX chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
Study: NCT04778644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gel capsule placebo
Study: NCT04838639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subjects per cohort will take a matched placebo.
Study: NCT05878158
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pulpotomy of immature permanent teeth
Study: NCT05085327
Drug: ChapStick Lip Moisturizer Original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05085327
Drug: ChapStick Lip Moisturizer Mint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT05085327
Drug: SPF Standard Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study: NCT04268706
Drug: CD30.CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
Study: NCT05219357
Drug: Usual-Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
Study: NCT05627791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
Study: NCT06462053
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda
Study: NCT04988841
Drug: Normacol
Normalized name: Normasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic enema solution
Study: NCT05687253
Drug: BX1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV BX1000
Study: NCT05164393
Drug: AVX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel treatment for once daily application
Study: NCT05712941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study: NCT06444997
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
Study: NCT04796714
Drug: Double antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sachet of aspirin 160 mg and one tablet of clopidogrel 75 mg per day.during 3 months
Study: NCT05077930
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
Study: NCT05815004
Drug: Enzyme Replacement Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: A hydrolytic lysosomal glucocerebrosidase-specific enzyme
Study: NCT03689114
Drug: Low dose oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 600 mg/die
Study: NCT03689114
Drug: Standard dose oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 1200 mg/die
Study: NCT05457582
Drug: Placebo plus high-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Study: NCT05457582
Drug: PCSK 9 Inhibitor plus high-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
Study: NCT00000801
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000801
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05845645
Drug: UCB0599
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
Study: NCT05555303
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In addition to the all-oral RR-TB treatment, add two intramuscular doses each consisting of 30 mg amikacin/kg, a first dose on day 1 and a second dose on day 4, all in the first week of treatment.~The amikacin solution will be admixed with a lidocaine solution in the syringe before administration.
Study: NCT05625698
Drug: MagTrace only
Approvals — FDA: no, EMA: no, PMDA: no
Description: see information in arm descriptions
Study: NCT05620316
Drug: BOTOX® Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MU of botulinum toxin type A (BOTOX® - Allergan Inc. - Dublin - Ireland) were diluted in 2ml of saline. Patients were injected with 10 MU of BTXA per side at two sites into the masseter muscle bilaterally. The first site was the inferior prominent part of the masseter muscle observed when the subject was asked to clench, and the other site was 5 mm below the first point
Study: NCT04738318
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
Study: NCT05249335
Drug: OST
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive Orafang for colonoscopy
Study: NCT05249335
Drug: 2L-PEG/Asc
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive 2L-PEG/Asc for colonoscopy
Study: NCT06236191
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin
Study: NCT04742907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo product
Study: NCT04743115
Drug: BS HH 002.SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL
Study: NCT06268652
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m² , PO, bid, days1-14, q3w
Study: NCT05976295
Drug: Jianpi Qushi Huatan Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.